In today’s briefing:
- Aier Eye Hospital (300015.CH) 22H1 – More Downside Ahead; The Long Logic Doesn’t Exist
- Agilent Technologies: New Launches In Mass Spectrometry & Other Drivers
- Pfizer Inc.: The Global Blood Therapeutics Acquisition & Other Drivers
Aier Eye Hospital (300015.CH) 22H1 – More Downside Ahead; The Long Logic Doesn’t Exist
- The fundamental changes in the population structure will lead to a decline in the growth rate of the total retail sales of consumer goods. The long logic doesn’t exist.
- Aier has hit a growth ceiling. As the endogenous demand will be stepped downward gradually, the performance of Aier will further decline. The downward elasticity of valuation is greater.
- It is still difficult for healthcare sector to have its own independent growth logic. The bottom of healthcare sector would appear after the collapse of Aier’s valuation.
Agilent Technologies: New Launches In Mass Spectrometry & Other Drivers
- Agilent Technologies delivered an excellent quarterly result with earnings and revenue exceeding market expectations significantly.
- The strong results were led by strength in its biggest markets i.e., chemical, energy, and pharma.
- We provide the stock of Agilent Technologies with a ‘Hold’ rating with a revision in the target price.
Pfizer Inc.: The Global Blood Therapeutics Acquisition & Other Drivers
- While operating in a difficult foreign exchange environment, Pfizer maintained a good operational performance in the second quarter and delivered an all-around beat, exceeding Wall Street expectations on all counts.
- The chance of a future variety that combines the severity of the original virus with the contagiousness of Omicron nevertheless persists.
- Among major updates, Pfizer went on to acquire Global Blood Therapeutics to strengthen its commitment to sickle cell disease.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars